AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24621971 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg
Number of subjects: 553
Study 24621971 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 3 g/day
Number of subjects: 553
Study 21149427 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air cleaners
Number of subjects: 225
Study 21149427 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive HEPA air cleaners)
Number of subjects: 225
Study 18367956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus recombinant factor VIII (rFVIII) 25 to 50 IU/kg given 6, 14, 24, 36, 48, and 60 hours after loading dose
Number of subjects: 14
Study 18367956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of recombinant factor VIII (rFVIII) 3 to 4 IU/kg per hour for 48 hours, followed by a bolus of 25 IU/kg at 60 hours
Number of subjects: 14
Study 18367956 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 100 IU/kg factor IX followed by bolus of 50 IU/kg at 3, 15, 27, and 48 hours
Number of subjects: 14
Study 18367956 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and fentanyl used in the first 8 patients
Number of subjects: 14
Study 17138770 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone, 5 mg daily for 26 weeks
Number of subjects: 42
Study 17138770 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 42
Study 14616871 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed rice formula (HRF)
Number of subjects: 18
Study 14616871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as part of the double-blind study)
Number of subjects: 18
Study 10601119 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (750 mL)
Number of subjects: 26
Study 10601119 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (150 mL)
Number of subjects: 26
Study 10601119 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution (750 mL)
Number of subjects: 26
Study 10601119 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (in controls)
Number of subjects: 26
Study 8911338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (3 minutes of aortic crossclamping followed by 2 minutes of reperfusion)
Number of subjects: 20
Study 8911338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preconditioning, 5 minutes of bypass)
Number of subjects: 20
Study 8911338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: All other substances (except PGF2 alpha)
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: All substances (except methacholine)
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandins (D2 and F2 alpha)
Number of subjects: 20
Study 2262647 — intervention group
Group type: EXPERIMENTAL
Intervention: All substances
Number of subjects: 20
Study 638119 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplements of 20-30 mg inorganic iron as ferrous sulphate for 3.5, 7, and 12 months
Number of subjects: 0
Study 638119 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 638119 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily requirements of energy and protein, plus 5 microgram cyanocobalamin and 200 microgram folic acid
Number of subjects: 0
Study 638119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe supplementation
Number of subjects: 0
Study 30944078 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical model of the knee/shoulder joint
Number of subjects: 52
Study 30944078 — intervention group
Group type: COMPARATOR
Intervention: Verbal explanation without a model
Number of subjects: 52
Study 25695618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 485
Study 25695618 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 485
Study 25695618 — intervention group
Group type: COMPARATOR
Intervention: Various cohorts
Number of subjects: 485
Study 23949018 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek silorane with silorane system adhesive (FS/SSA)
Number of subjects: 24
Study 23949018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceram X mono with Clearfil SE (CXM/CSE)
Number of subjects: 24
Study 23949018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceram X mono with XP bond (CXM/XPB)
Number of subjects: 24
Study 23949018 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 24
Study 22051162 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 50
Study 22051162 — intervention group
Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 50
Study 19348538 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting respiratory sinus arrhythmia (RSAREST)
Number of subjects: 80
Study 17469936 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (1.75 mg/kg, 3.50 mg/kg, or 7.00 mg/kg)
Number of subjects: 11
Study 17469936 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (0.035 mg/kg, 0.070 mg/kg, 0.140 mg/kg)
Number of subjects: 11
Study 17469936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15243523 — intervention group
Group type: EXPERIMENTAL
Intervention: UV exposure
Number of subjects: 14
Study 12478328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine 1% cream
Number of subjects: 189
Study 12478328 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 189
Study 9809846 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (100 mg x kg(‐1) administered at 0, 30, 60, and 90‐min post‐race)
Number of subjects: 16
Study 9809846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 16
Study 9809846 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 16
Study 9809846 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies with glutamine
Number of subjects: 16
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-schizophrenic boys at age 7
Number of subjects: 0
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-schizophrenic boys at age 11
Number of subjects: 0
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-schizophrenic girls at age 11
Number of subjects: 0
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-affective psychotic boys at age 7
Number of subjects: 0
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-affective psychotic boys at age 11
Number of subjects: 0
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-schizophrenics at ages 7, 11, and 16
Number of subjects: 0
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenics-to-be at age 7
Number of subjects: 0
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenics-to-be at age 16
Number of subjects: 0
Study 7654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with non-psychotic diagnoses at age 11
Number of subjects: 0
Study 3148282 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-component extract
Number of subjects: 39
Study 3148282 — intervention group
Group type: COMPARATOR
Intervention: 2-component extract
Number of subjects: 39
Study 3148282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 29680102 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent VTE (rVTE)
Number of subjects: 883
Study 29680102 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 883
Study 28031044 — intervention group
Group type: EXPERIMENTAL
Intervention: MediMind
Number of subjects: 183
Study 28031044 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Training
Number of subjects: 183
Study 28031044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 183
Study 25703086 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once-daily plus asunaprevir 100 mg twice-daily, with weekly peginterferon alfa-2a and weight-based ribavirin for 24 weeks
Number of subjects: 398
Study 25703086 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir plus asunaprevir and peginterferon/ribavirin
Number of subjects: 398
Study 24319685 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated arterial line filter (Group In)
Number of subjects: 36
Study 24319685 — intervention group
Group type: COMPARATOR
Intervention: Nonintegrated arterial line filter (Group NIn)
Number of subjects: 36
Study 20965319 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic product containing Lactobacillus gasseri CHO-220 and inulin
Number of subjects: 32
Study 20965319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18221638 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplemented diet (EPA + DHA, enriched in salmon 150 g/day, 3 times/week)
Number of subjects: 35
Study 18221638 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study 18221638 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon diet (150 g/day, 3 times/week)
Number of subjects: 35
Study 20577971 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive depression screen during hospitalization
Number of subjects: 738
Study 20577971 — intervention group
Group type: COMPARATOR
Intervention: No depression (control group)
Number of subjects: 738
Study 16313140 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 48
Study 16313140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16313140 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 48
Study 16313140 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 48
Study 11568790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg intramuscularly
Number of subjects: 95
Study 11568790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg orally
Number of subjects: 95
Study 11568790 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy
Number of subjects: 95
Study 9783928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with mitomycin C (40 mg) followed by BCG (6 weekly instillations)
Number of subjects: 182
Study 9783928 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C only (10 weekly instillations)
Number of subjects: 182
Study 7848896 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release isosorbide dinitrate (ISDN) 15-120 mg in a qid regimen
Number of subjects: 0
Study 7848896 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric tid therapy with 30 mg of ISDN (7 a.m., 1 p.m., and 6 p.m.)
Number of subjects: 0
Study 7848896 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric bid therapy with ISDN at 7 a.m. and noon
Number of subjects: 0
Study 7848896 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release isosorbide-5-mononitrate (IS-5-MN) 10 and 20 mg given bid
Number of subjects: 0
Study 7848896 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily controlled-release IS-5-MN 120 and 240 mg
Number of subjects: 0
Study 7848896 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric bid immediate-release IS-5-MN
Number of subjects: 0
Study 7848896 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily controlled-release IS-5-MN
Number of subjects: 0
Study 3140580 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17HPC, Proluton Depot) 500 mg intramuscularly weekly for 6-16 weeks
Number of subjects: 40
Study 3140580 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17HPC) when pregnancy was suspected
Number of subjects: 40
Study 3140580 — intervention group
Group type: COMPARATOR
Intervention: 17 alpha-hydroxyprogesterone caproate (17HPC) 500 mg intramuscularly weekly
Number of subjects: 40
Study 3140580 — intervention group
Group type: COMPARATOR
Intervention: 17 alpha-hydroxyprogesterone caproate (17HPC) 250 mg intramuscularly weekly
Number of subjects: 40
Study 3140580 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive pill (Microgynon)
Number of subjects: 40
Study 3140580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3140580 — intervention group
Group type: EXPERIMENTAL
Intervention: 17HPC
Number of subjects: 40
Study 31718087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based IARA Model® training
Number of subjects: 497
Study 31718087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 497
Study 30036596 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ACE inhibitor-associated angioedema
Number of subjects: 0
Study 30036596 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor-treated controls
Number of subjects: 0
Study 26871954 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (1 ml of 40 mg/ml methylprednisolone dissolved in 4 ml lidocaine)
Number of subjects: 100
Study 26871954 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (1 ml isotonic saline mixed with 4 ml lidocaine)
Number of subjects: 100
Study 24652032 — intervention group
Group type: EXPERIMENTAL
Intervention: SC with iPad
Number of subjects: 90
Study 24652032 — intervention group
Group type: COMPARATOR
Intervention: Standard Counseling (SC)
Number of subjects: 90
Study 22708259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid titration (initial dosage 100 mg/day increased by 100-200 mg at weekly intervals)
Number of subjects: 183
Study 22708259 — intervention group
Group type: COMPARATOR
Intervention: Slow titration (initial dosage 50 mg/day increased in 50 mg/day increments at weekly intervals)
Number of subjects: 183
Study 22708259 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow titration
Number of subjects: 183
Study 22708259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid titration
Number of subjects: 183
Study 19461385 — intervention group
Group type: EXPERIMENTAL
Intervention: FES cycling
Number of subjects: 0
Study 19461385 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive cycling
Number of subjects: 0
Study 19461385 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation exercise without cycling
Number of subjects: 0
Study 17167261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish (FV)
Number of subjects: 11
Study 17167261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish with toothbrush abrasion (FV‐er+abr)
Number of subjects: 11
Study 17167261 — intervention group
Group type: COMPARATOR
Intervention: Control group with erosion only (C‐er)
Number of subjects: 11
Study 17167261 — intervention group
Group type: COMPARATOR
Intervention: Control group with erosion and toothbrush abrasion (C‐er+abr)
Number of subjects: 11
Study 15076242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogue treatment; venous lactate measured according to AACTG guidelines.
Number of subjects: 83
Study 11685979 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 10
Study 11685979 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 10
Study 9669015 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoallergen tape (group T)
Number of subjects: 150
Study 9669015 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloromycetin ointment (group O)
Number of subjects: 150
Study 9669015 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 150
Study 7836027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training for 6 weeks (60 min twice a week) in RA-TG
Number of subjects: 30
Study 7836027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training (home-training) for another 6 months in RA-TG
Number of subjects: 30
Study 7836027 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (healthy-TG)
Number of subjects: 30
Study 7836027 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) for both RA and healthy subjects
Number of subjects: 30
Study 7836027 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of beta-EP levels between RA-TG and healthy-TG after training
Number of subjects: 30
Study 7836027 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of beta-LPH levels between RA-TG and healthy-TG after training
Number of subjects: 30
Study 3278390 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation concurrent with cisplatinum
Number of subjects: 5500
Study 3278390 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 5500
Study 3278390 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen (95% O2 and 5% CO2) breathing or misonidazole during radiotherapy
Number of subjects: 5500
Study 3278390 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosensitizer SR 2508
Number of subjects: 5500
Study 3278390 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-course irradiation
Number of subjects: 5500
Study 3278390 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice a day irradiation with 120 cGys up to 6,000 cGys
Number of subjects: 5500
Study 29882318 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11 for Health intervention (11-week program, 2 sessions/week of 45 minutes)
Number of subjects: 392
Study 29882318 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11 for Health intervention
Number of subjects: 392
Study 29882318 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular activities)
Number of subjects: 392
Study 28065181 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier snack bar (consumed for 6 weeks)
Number of subjects: 28
Study 28065181 — intervention group
Group type: COMPARATOR
Intervention: Delayed receipt of healthier snack bar (control group)
Number of subjects: 28
Study 24836961 — intervention group
Group type: EXPERIMENTAL
Intervention: T100/eFlow
Number of subjects: 58
Study 24836961 — intervention group
Group type: COMPARATOR
Intervention: TNS/PARI LC PLUS
Number of subjects: 58
Study 23184140 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological material TOT (PELVILACE® TO)
Number of subjects: 100
Study 23184140 — intervention group
Group type: COMPARATOR
Intervention: Synthetic material TOT (ALIGN®TO Urethral Support System)
Number of subjects: 100
Study 20189705 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS-qualified anaesthetist
Number of subjects: 36
Study 20189705 — intervention group
Group type: COMPARATOR
Intervention: ALS-qualified non-anaesthetist
Number of subjects: 36
Study 18394162 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated; DrotAA) at a dosage of 24 mug/kg per hour for 96 hours
Number of subjects: 2225
Study 18394162 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated; DrotAA)
Number of subjects: 2225
Study 18394162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2225
Study 16797936 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 20
Study 16797936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12419011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience condition
Number of subjects: 312
Study 12419011 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 312
Study 10613302 — intervention group
Group type: COMPARATOR
Intervention: RT plus PCV
Number of subjects: 281
Study 10613302 — intervention group
Group type: EXPERIMENTAL
Intervention: RT/BUdR plus PCV
Number of subjects: 281
Study 7486780 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial screening by senior surgical staff
Number of subjects: 0
Study 1785247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atropine 0.03 mg/kg (Group A)
Number of subjects: 58
Study 1785247 — intervention group
Group type: COMPARATOR
Intervention: i.v. glycopyrrolate 0.005 mg/kg (Group G)
Number of subjects: 58
Study 7211903 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon catheters
Number of subjects: 954
Study 7211903 — intervention group
Group type: COMPARATOR
Intervention: Steel needles
Number of subjects: 954
Study 7211903 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 954
Study 7211903 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration
Number of subjects: 954
Study 31860598 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed jaw thrust
Number of subjects: 106
Study 31860598 — intervention group
Group type: COMPARATOR
Intervention: Conventional intubation with sham jaw thrust
Number of subjects: 106
Study 30777736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular distraction osteogenesis (MDO)
Number of subjects: 18
Study 30777736 — intervention group
Group type: COMPARATOR
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 18
Study 28082176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tDCS (2 mA, 10 daily sessions of 20 minutes) and VRT
Number of subjects: 7
Study 28082176 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation with compensatory eye movement and exploration training (Control)
Number of subjects: 7
Study 25624343 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes mellitus and hypertension combined group
Number of subjects: 1609
Study 25624343 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus and hypertension combined group
Number of subjects: 1609
Study 25624343 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose level within prediabetic range
Number of subjects: 1609